Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting

J. Kopecký, M. Pásek, R. Lakomý, B. Melichar, I. Mrazová, O. Kubeček, M. Arenbergerová, R. Lemstrová, A. Švancarová, V. Tretera, A. Hlodáková, K. Žváčková

. 2024 ; 13 (5) : e6982. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006820

Grantová podpora
Cooperation Program, research area ONCO
Q40/11 Charles University Faculty of Medicine in Hradec Kralove
Q40/06 Charles University Faculty of Medicine in Hradec Kralove

BACKGROUND: Immunotherapy and targeted therapy are currently two alternative backbones in the therapy of BRAF-mutated malignant melanoma. However, predictive biomarkers that would help with treatment selection are lacking. METHODS: This retrospective study investigated outcomes of anti-programmed death receptor-1 monotherapy and targeted therapy in the first-line setting in patients with metastatic BRAF-mutated melanoma, focusing on clinical and laboratory parameters associated with treatment outcome. RESULTS: Data from 174 patients were analysed. The median progression-free survival (PFS) was 17.0 months (95% CI; 8-39) and 12.5 months (95% CI; 9-14.2) for immunotherapy and targeted therapy, respectively. The 3-year PFS rate was 39% for immunotherapy and 25% for targeted therapy. The objective response rate was 72% and 51% for targeted therapy and immunotherapy. The median overall (OS) survival for immunotherapy has not been reached and was 23.6 months (95% CI; 16.1-38.2) for targeted therapy, with a 3-year survival rate of 63% and 40%, respectively. In a univariate analysis, age < 70 years, a higher number of metastatic sites, elevated serum LDH and a neutrophil-lymphocyte ratio above the cut-off value were associated with inferior PFS regardless of the therapy received, but only serum LDH level and the presence of lung metastases remained significant predictors of PFS in a multivariate analysis. CONCLUSIONS: Present real-world data document the high effectiveness of immunotherapy and targeted therapy. Although targeted therapy had higher response rates, immunotherapy improved PFS and OS. While the prognostic value of LDH was confirmed, the potential use of blood cell count-derived parameters to predict outcomes needs further investigation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006820
003      
CZ-PrNML
005      
20240423155519.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cam4.6982 $2 doi
035    __
$a (PubMed)38491825
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kopecký, Jindřich $u Department of Clinical Radiotherapy and Oncology, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000241260410 $7 xx0129613
245    14
$a The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting / $c J. Kopecký, M. Pásek, R. Lakomý, B. Melichar, I. Mrazová, O. Kubeček, M. Arenbergerová, R. Lemstrová, A. Švancarová, V. Tretera, A. Hlodáková, K. Žváčková
520    9_
$a BACKGROUND: Immunotherapy and targeted therapy are currently two alternative backbones in the therapy of BRAF-mutated malignant melanoma. However, predictive biomarkers that would help with treatment selection are lacking. METHODS: This retrospective study investigated outcomes of anti-programmed death receptor-1 monotherapy and targeted therapy in the first-line setting in patients with metastatic BRAF-mutated melanoma, focusing on clinical and laboratory parameters associated with treatment outcome. RESULTS: Data from 174 patients were analysed. The median progression-free survival (PFS) was 17.0 months (95% CI; 8-39) and 12.5 months (95% CI; 9-14.2) for immunotherapy and targeted therapy, respectively. The 3-year PFS rate was 39% for immunotherapy and 25% for targeted therapy. The objective response rate was 72% and 51% for targeted therapy and immunotherapy. The median overall (OS) survival for immunotherapy has not been reached and was 23.6 months (95% CI; 16.1-38.2) for targeted therapy, with a 3-year survival rate of 63% and 40%, respectively. In a univariate analysis, age < 70 years, a higher number of metastatic sites, elevated serum LDH and a neutrophil-lymphocyte ratio above the cut-off value were associated with inferior PFS regardless of the therapy received, but only serum LDH level and the presence of lung metastases remained significant predictors of PFS in a multivariate analysis. CONCLUSIONS: Present real-world data document the high effectiveness of immunotherapy and targeted therapy. Although targeted therapy had higher response rates, immunotherapy improved PFS and OS. While the prognostic value of LDH was confirmed, the potential use of blood cell count-derived parameters to predict outcomes needs further investigation.
650    _2
$a lidé $7 D006801
650    _2
$a senioři $7 D000368
650    12
$a melanom $x farmakoterapie $x genetika $x patologie $7 D008545
650    _2
$a protoonkogenní proteiny B-Raf $x genetika $7 D048493
650    _2
$a retrospektivní studie $7 D012189
650    12
$a nádory kůže $x farmakoterapie $7 D012878
650    _2
$a receptory domény smrti $7 D053218
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pásek, Marek $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic $1 https://orcid.org/0009000008758332
700    1_
$a Lakomý, Radek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000349610339
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic $1 https://orcid.org/0000000254746866
700    1_
$a Mrazová, Ivona $u Department of Oncology, County Hospital, České Budějovice, Czech Republic
700    1_
$a Kubeček, Ondřej $u Department of Clinical Radiotherapy and Oncology, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic $1 https://orcid.org/000000032105625X $7 xx0209606
700    1_
$a Arenbergerová, Monika $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000279199619 $7 xx0074761
700    1_
$a Lemstrová, Radmila $u Department of Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic $1 https://orcid.org/0000000281772605
700    1_
$a Švancarová, Alžběta $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Tretera, Vojtěch $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic $1 https://orcid.org/0009000255576026
700    1_
$a Hlodáková, Alžběta $u Department of Clinical Radiotherapy and Oncology, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Žváčková, Kamila $u Department of Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital, Olomouc, Czech Republic
773    0_
$w MED00181704 $t Cancer medicine $x 2045-7634 $g Roč. 13, č. 5 (2024), s. e6982
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38491825 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155516 $b ABA008
999    __
$a ok $b bmc $g 2081039 $s 1216587
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 13 $c 5 $d e6982 $e - $i 2045-7634 $m Cancer medicine $n Cancer Med $x MED00181704
GRA    __
$p Cooperation Program, research area ONCO
GRA    __
$a Q40/11 $p Charles University Faculty of Medicine in Hradec Kralove
GRA    __
$a Q40/06 $p Charles University Faculty of Medicine in Hradec Kralove
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...